Lupin posts Q3 loss of ₹152 crore on one-off charge1 min read . Updated: 06 Feb 2019, 03:40 PM IST
- Lupin reported a one-time charge of Rs. 342 crore in the third quarter
- The company had reported a profit of Rs. 222 crore in the same quarter last year
Bengaluru: Indian drugmaker Lupin Ltd posted a surprise quarterly loss on Wednesday after taking a one-time charge related to litigation over a blood pressure drug.
Lupin made a provision of ₹342 crore ($47.7 million) after the General Court of the European Union in December upheld a 2014 European Commission decision on a fine against Lupin related to the blood pressure drug Perindopril, it said.
Lupin had a net loss of ₹152 crore compared to a profit of ₹222 crore in the same quarter last year, the company said.
An average of estimates from 18 analysts had expected a profit of ₹289 crore, according to Refinitiv Eikon data.
Lupin's sales rose 12.2% to ₹4,370 crore in the quarter. Revenue from North America, which accounted for nearly a third of total revenue, slipped 1 percent.
"After a tough H1, we are now starting to see growth in the U.S.," said Nilesh Gupta, managing director of Lupin Ltd.
Indian pharmaceutical companies have struggled with weak sales in the US on account of regulatory bans and warnings over quality control at production plants. Sales have also been hit by pricing pressures as competition heats up in the US generics market.
The company's revenue in India jumped 11.4% to ₹1,190 crore.
Shares of Lupin fell 1.2% after the results were announced, while the broader Mumbai market rose over 1%.
The story has been published from a wire agency feed without modifications to the text. Only the headline has been changed